Newron Pharmaceuticals S.p.A. announced that Margarita Chavez has been appointed as an advisor to the Board of Directors of Newron, bringing significant pharmaceutical business development (BD) and dealmaking expertise. It is intended that Margarita Chavez will be nominated for election to the Board of Directors at Newron?s next Ordinary Annual General Meeting (AGM) of Shareholders in spring 2024. Margarita Chavez brings to Newron over 20 years of dealmaking expertise and leadership in the pharmaceutical industry.

Most recently, she was Managing Director of AbbVie Ventures and served as a board member of several U.S. - based biotech companies. As a Director in Abbott?s Global Pharmaceutical Licensing & Acquisitions Division, she was involved in the successful in-licensing of Elagolix and the acquisitions of Solvay, ImmuVen and the Lupron franchise. Before joining Abbott, Ms. Chavez practiced as a corporate and securities lawyer in the Silicon Valley, advising tech and biotech companies on strategic transactions including IPOs and mergers and acquisitions.

She received her bachelor?s degree from Santa Clara University and her juris doctor from Santa Clara University School of Law (both California).